Table 1.
Demographic, anthropometric, and traditional cardiovascular risk characteristics of Allo-SCT survivors and Controls.
| Allo-SCT survivors | Controls | P | |
|---|---|---|---|
| Age, years | 44 ± 15 | 46 ± 13 | 0.75 |
| Male sex, n (%) | 7 (50) | 7 (50) | > 0.99 |
| Height, m | 1.72 ± 0.95 | 1.73 ± 0.82 | 0.65 |
| Weight, kg | 72.3 ± 14.8 | 72.2 ± 15.4 | 0.99 |
| Body mass index, kg.m-2 | 24.4 ± 3.9 | 23.9 ± 3.6 | 0.71 |
| Body surface area, m-2 | 1.85 ± 0.23 | 1.85 ± 0.24 | 0.97 |
| Cardiovascular risk profile, n (%) | |||
| Overweight | 8 (57) | 6 (43) | 0.71 |
| Hypertension | 4 (29) | 0 (0) | 0.097 |
| Hyperlipidaemia | 1 (7) | 0 (0) | > 0.99 |
| Diabetic | 1 (7) | 0 (0) | > 0.99 |
| History of CVD Event | 2 (14) | 0 (0) | 0.48 |
| ≥ 1 risk factor | 11 (79) | 6 (43) | 0.12 |
| Cardiovascular medication, n (%) | |||
| Statin | 1 (7) | 0 (0) | > 0.99 |
| ACE-I/ARB | 3 (21) | 0 (0) | 0.22 |
| Beta-blocker | 1 (7) | 0 (0) | > 0.99 |
| Vasodilator | 1 (7) | 0 (0) | > 0.99 |
Data are mean ± SD or n (%); Abbreviations: ACE-I, angiotensin-converting-enzyme inhibitors; ARB angiotensin II receptor blockers; CVD cardiovascular disease.